La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Infinity Pharmaceuticals Dividende

Dividende contrôle des critères 0/6

Infinity Pharmaceuticals n'a pas d'antécédents de versement de dividendes.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	2.0%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-US$0.45
Prévision de rendement du dividende	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29

Investigating Infinity Pharmaceuticals

Nov 25

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Jan 06

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Dec 09

Infinity Pharmaceutical Reaching Vital New Staging Posts

Dec 01

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de INFI.Q ont été stables dans le passé.

Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de INFI.Q ont augmenté.

Rendement des dividendes par rapport au marché

Infinity Pharmaceuticals Rendement des dividendes par rapport au marché

Comment le rendement du dividende de INFI.Q se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (INFI.Q)	n/a
25% du marché (US)	1.4%
25% du marché (US)	4.4%
Moyenne du secteur (Biotechs)	2.0%
Analyste prévisionnel (INFI.Q) (jusqu'à 3 ans)	n/a

Dividende notable: Impossible d'évaluer le rendement des dividendes de INFI.Q par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.

Dividende élevé: Impossible d'évaluer le rendement des dividendes de INFI.Q par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.

Bénéfice distribué aux actionnaires

Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de INFI.Q afin de déterminer si ses paiements de dividendes sont couverts par les bénéfices.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car INFI.Q n'a signalé aucun versement.

Infinity Pharmaceuticals Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 20% to US$4.00

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Consensus revenue estimates increase by 276%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Consensus estimates of losses per share improve by 10%

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 20%

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.67

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Consensus revenue estimates increase by 232%

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$9.00

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Price target increased to US$9.71

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Investigating Infinity Pharmaceuticals

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Consensus revenue estimates increase to US$1.89m

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Consensus forecasts updated

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: US$5.36

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

New 90-day high: US$2.80

Infinity Pharmaceuticals, Inc. Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Infinity Pharmaceuticals, Inc. Announces Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

New 90-day high: US$2.16

Infinity Pharmaceutical Reaching Vital New Staging Posts

Analysts update estimates

New 90-day high: US$1.51

Revenue and earnings beat expectations

Third quarter 2020 earnings released: US$0.16 loss per share

Infinity Pharmaceuticals, Inc. Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer (SITC)

Infinity Receives Fast Track Designation for Eganelisib in Combination with a Checkpoint Inhibitor and Chemotherapy for First-Line Treatment of Advanced TNBC

New 90-day high - US$1.17

Price target raised to US$2.17